Document:

Exhibit

Exhibit 10.20

CONFIDENTIAL TREATMENT REQUESTED
 
Certain portions of this document have been omitted pursuant to a request for Confidential Treatment and, where applicable, have been marked with “[***]” to indicate where omissions have been made. The confidential material has been filed separately with the Securities and Exchange Commission.

ESTABLISHMENT LABS S.A.
AND
THE HOSPITAL GROUP

SUPPLY AGREEMENT

Supply Agreement
The following Supply Agreement is entered  
BY AND BETWEEN :
ESTABLISHMENT LABS S.A., a corporation organized under the laws of Costa Rica, having its registered office located in Zona Franca Coyol, Costa Rica, with company ID number 3-101-366337, (Hereinafter referred to as “ESTABLISHMENT”)
Represented by Juan Jose Chacan Quiros, CEO;
AND
THE PURCHASER, as defined in the previous Data Sheet
Hereinafter individually or collectively referred to as the “Parties”.
WITNESSETH
1.    WHEREAS ESTABLISHMENT has developed and manufactures a range of mammary implants and related products under the trademark MOTIVA IMPLANT MATRIX®.
2.    WHEREAS THE PURCHASER is willing to purchase MOTIVA IMPLANT MATRIX® products brand to be used in its facilities (as defined below – see article 1.15), all on the terms and under the conditions set forth below.
NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS:
ARTICLE I - DEFINITIONS
As used in this Agreement, the singular shall include the plural and the plural shall include the singular, wherever so required by fact or context.  Titles used in the articles hereof shall be only for the sake of convenience and shall not be regarded as a part of this Agreement.  Exhibit means any exhibit to this Agreement, each of them being made an integral part hereof.  As used in and for the sole purpose of this Agreement, and unless otherwise provided, the following terms shall have the meaning set forth below:
1.1    “Affiliate” shall mean any corporation or other business entity controlled by, controlling or under common control with a Party to this Agreement.  For this purpose “control” shall mean (i) direct or indirect beneficial ownership of fifty percent (50%) or more of the voting stock, or (ii) a fifty percent (50%) or more interest in the income of such corporation or other business entity or (iii) direct or indirect power to direct or cause the direction of the management and policies by any means whatsoever.
1.2    “Agreement” shall mean the present purchase agreement.
1.3    “Calendar Year” means each twelve-month period starting on 1 January and ending 31 December.

-1-

1.4    “Commercial Year” shall mean each twelve (12) months’ period starting on the date of this agreement and ending on its anniversary.
1.5    “Effective Date” shall mean the date of signature of the Agreement.
1.6    “Minimum Net Purchases” shall mean the minimum Net Purchases (as hereinafter defined) EXW value (EDC) of Products as per ICC Incoterms (2000 Edition) that THE PURCHASER commits to attain each Commercial Year with ESTABLISHMENT, as indicated in Article 9 hereof.
1.7    “Net Purchases” shall mean the actual selling prices charged by ESTABLISHMENT to THE PURCHASER in bona fide, as per invoices covering the sales less all rebates, returns, trade and cash discounts and all taxes.
1.8    “Product(s)” shall collectively mean the MOTIVA IMPLANT MATRIX® range of breast implants and related products, conceived, developed and marketed by ESTABLISHMENT listed in EXHIBIT I (A).  This shall also include any new MOTIVA IMPLANT MATRIX® product(s) that ESTABLISHMENT will decide to launch in the Territory;
1.9    “Product(s) Price(s)” shall mean the EXW EDC (Incoterms 2000) prices of Products, supplied by ESTABLISHMENT to THE PURCHASER, as determined from time to time in accordance with article 11.2 herein.
1.10    “Physicians” shall mean exclusively the physicians working in the PURCHASER’s facilities.
1.11    “Quality Agreement” means the document relating to the medical devices of the brand MOTIVA IMPLANT MATRIX® set out in EXHIBIT IV hereto.
1.12    “Third Party” means any party other than THE PURCHASER, ESTABLISHMENT or their respective Affiliates.
ARTICLE 2 – SUBJECT MATTER OF THE AGREEMENT
2.1    ESTABLISHMENT hereby grants THE PURCHASER which in turn accepts, the right to import, store into its warehouse sites located in the addresses indicated in the Data Sheet, promote, and employ the Products under the Trademarks through the Physicians in its facilities.
2.2    Subject to prior agreement between the Parties, with respect to specific commercial terms (such as Minimum Net Purchases, invoices and prices), this Agreement may be extended by an amendment to cover any new MOTIVA IMPLANT MATRIX® product launched by ESTABLISHMENT.
2.3    In consideration of the rights hereby granted, THE PURCHASER agrees to perform and be responsible for all operations of import, returns, traceability, and in general all operations relating to maintaining availability and the offering of the Products to the Physicians 

-2-

working at its facilities, in accordance with the terms and conditions of this Agreement and all medical rules and laws which may apply.
2.4    ESTABLISHMENT undertakes to meet THE PURCHASER’s requirements for the Products and to sell the Products to THE PURCHASER at the prices hereto agreed.
2.5    ESTABLISHMENT shall be entitled to:
2.5.1    Invoice THE PURCHASER upon shipment of the Products.
2.5.2    At any time and at its discretion, without the consent of THE PURCHASER, to make any change or introduce any modification, new presentation, enhancement or improvement to any of the Products; and/or introduce new additional or replacement Products; and such alteration in the products shall become Products for the purposes of this Agreement;
2.5.3    Whether or not requested by THE PURCHASER, at its sole discretion assist THE PURCHASER in promoting the sales of the Products.
2.6    THE PURCHASER undertakes and agrees with ESTABLISHMENT at all times during the term of this Agreement:
2.6.1    to pay in full and in Pounds (GBP) each invoice issued by ESTABLISHMENT within the term granted as indicated in the Data Sheet from the date of the invoice thereafter.
2.6.2    to use its best endeavors to promote the use of the Products by its patients and Physicians and any line extensions or new products within the range to ESTABLISHMENT’S satisfaction.
2.6.3    to employ or engage a sufficient number of suitably qualified personnel to ensure the proper fulfillment of THE PURCHASER’s obligations under this Agreement;
2.6.4    to maintain an inventory of the Products at levels which are appropriate and adequate to meet the demand;
2.6.5    to keep all stocks of the Products which it holds in conditions appropriate for their storage and to provide security for the Products all at its own cost and according to this Agreement;
2.6.6    to inform ESTABLISHMENT immediately of any change in its organization or method of doing business which may affect the performance of THE PURCHASER’s duties in this Agreement;
2.6.7    not to use or make reference to or authorize others to use or make reference to, ESTABLISHMENT’s name, emblems or symbols in relation to the Products in any 

-3-

manner whatsoever, save where approved by ESTABLISHMENT in the case of packaging requirements;
2.6.8    to fully and effectively indemnify ESTABLISHMENT for each breach by THE PURCHASER of any of the provision of this Agreement.
ARTICLE 3 –TERM
3.1    This Agreement will become effective as of the Effective Date and unless otherwise prematurely terminated as provided herein, shall remain in full force and effect for a term of three (3) Commercial Years, i.e. until the Final Date indicated in the Data Sheet.
3.2    Thereafter, unless otherwise terminated by any Party giving the other six (6) months’ prior notice before any expiry, this Agreement will be renewed for successive periods of three (3) Commercial Years.
ARTICLE 4 –TRADEMARKS
4.1    The Products will be exclusively marketed under the Trademarks.  In addition, all packaging and documents will bear ESTABLISHMENT logo.
4.2    THE PURCHASER acknowledges the exclusive right, title and interest of ESTABLISHMENT or its Affiliate(s) in and to the Trademarks and to ESTABLISHMENT logo and will not do or cause to be done any act or thing contesting or, in any way, impairing or tending to impair any part of said right, title and interest, for the duration of this Agreement and after its expiry.
Furthermore, THE PURCHASER agrees not to register or acquire domain names which they know are identical or confusingly similar to the Trademark and/or the Logo or which include all or part of said Trademark and/or Logo for the duration of the Agreement and after its expiry.
4.3    THE PURCHASER shall notify ESTABLISHMENT promptly of any infringement of the Trademarks and ESTABLISHMENT logo and of any unfair competition coming to its attention.  THE PURCHASER will not take any action either amicable or legal, and will let ESTABLISHMENT take any action suitable in its judgment providing that, at ESTABLISHMENT’s request, THE PURCHASER shall collaborate in said amicable or legal action taken by ESTABLISHMENT or its representative.
ARTICLE 5 –COMMERCIAL AND MARKETING POLICY
5.1    During the last semester of each Commercial Year, ESTABLISHMENT and THE PURCHASER will meet at mutually convenient time and place in order to define jointly the commercial and marketing and merchandising policy to be applied for the next Commercial Year, said policy shall take into consideration ESTABLISHMENT’s international strategy for such Products including ESTABLISHMENT’s international merchandising introduction strategy.

-4-

5.2    THE PURCHASER agrees to employ the Products only through its clinics and qualified Physicians.
ARTICLE 6 –SALES PROMOTION AND ADVERTISING
6.1    As described hereinafter, every Commercial Year, THE PURCHASER will devote thereto an overall Budget as previously informed to ESTABLISHMENT for each Commercial Year.
6.2    The policy regarding media advertising and sales promotion will be mutually agreed each Commercial Year.
Regarding the merchandising policy, Products introduction should be performed by THE PURCHASER in accordance with ESTABLISHMENT’s merchandising recommendations as approved in the marketing plan.
6.3    In order to inform THE PURCHASER, ESTABLISHMENT may provide THE PURCHASER with samples of advertising material used in other territories.  THE PURCHASER undertakes not to create and use any promotion material in whatever form and aid (such as internet) without ESTABLISHMENT’s prior written consent.
ARTICLE 7 –MINIMUM NET PURCHASES, SHIPMENTS AND PRICES
7.1    For the duration of this Agreement, THE PURCHASER agrees to achieve each Commercial Year the Minimum Net Purchases as indicated in the Data Sheet.  The Minimum Net Purchases indicated for each year shall be divided by four to control progress during each quarter.
7.2    In case of non compliance during any Commercial Year, or during any quarter of such year, with any of the Minimum Net Purchases figures as indicated above, ESTABLISHMENT may increase or stop offering the special prices contained in the Agreement, and begin using the regular list prices for Europe for the Products, as indicated in 12.6 below.
7.3    In any Commercial Year of this Agreement, to the extent that THE PURCHASER’s non-compliance with the Minimum Net Purchases figures referred to above is due to ESTABLISHMENT’s failure to supply THE PURCHASER with Products on time and in full, such lost sales shall be included in any event in the calculation of the Minimum Net Purchases to be achieved in that Commercial Year by THE PURCHASER.
For the purposes of clarification, ESTABLISHMENT shall be entitled to deliver to PURCHASER plus or minus twenty per cent (20%) of all quantities of Products ordered by THE PURCHASER and account shall be taken of this fact in determining if ESTABLISHMENT has supplied THE PURCHASER with Product on time and in full in any given Commercial Year.

-5-

ARTICLE 8 –PRICES AND SHIPMENTS
8.1    For the term of this Agreement, ESTABLISHMENT agrees to have THE PURCHASER supplied with, and THE PURCHASER agrees to buy from ESTABLISHMENT most of its requirements of the Products.
8.2    
8.2.1    The Products will be supplied by ESTABLISHMENT, EXW EDC as per ICC Incoterms (2000 Edition) at the prices as indicated in EXHIBIT I hereto.
8.2.2    The Products Prices shall be maintained during the year of the Execution Date of this Agreement.  Thereafter, said Products Prices shall be revised once every calendar year after mutual consultation, with variations being effective every January 1st.
Market conditions, prices of the raw material as well as volume of business between the Parties shall be taken into account in establishing the Products Prices.  Should on November 30th at the latest no agreement be reached between the Parties hereto with respect to the level of said price increase, the prices of the Products will be increased only up to five per cent (5%).
8.2.3    Once the Products are delivered, THE PURCHASER undertakes to store them in its warehouses located as indicated in the Data Sheet, which warehouses complies with the storage conditions of the Products as described in the Exhibits.
8.3    
8.3.1    Each invoice will be sent by ESTABLISHMENT to THE PURCHASER and will be paid by THE PURCHASER by bank transfer in Pounds within the term indicated in the Data Sheet from the date of the invoice, with a credit limit as indicated in the Data Sheet (hereinafter referred to as the “Authorized Facility”) unless otherwise agreed to in writing by the parties.
THE PURCHASER acknowledges and agrees that, during the term of the Agreement, the amount of the Authorized Facility, or the term granted for such credit, could be modified by ESTABLISHMENT, depending on the PURCHASER’s payment record or current market conditions.
8.3.2    In the event that THE PURCHASER desires to place an order of Products for an amount exceeding the Authorized Facility, THE PURCHASER shall obtain ESTABLISHMENT’s prior consent.  In case of refusal, THE PURCHASER shall secure said new order providing ESTABLISHMENT with:
		
	-
	either a guaranty or bond in a form acceptable to ESTABLISHMENT, said guaranty to be maintained until the order concerned is fully paid;

-6-

		
	-
	or a bank guarantee or letter of credit opened by a local first class bank confirmed by a first class bank acceptable to ESTABLISHMENT, said guaranty to be maintained until the order concerned is fully paid;

		
	-
	or prepayment of the order or the excess

8.4    
8.4.1    Within ten (10) days from date of receipt, THE PURCHASER shall conduct a visual inspection of the Products delivered by ESTABLISHMENT for damage, defects or shortage.  After such ten (10) days, if no notice to ESTABLISHMENT is made regarding damages, defects or shortage, the Products will be considered accepted by THE PURCHASER, provided however that in the event of latent defects of the Product not reasonably detected in connection with the visual inspection, THE PURCHASER shall notify ESTABLISHMENT promptly in writing upon detection thereof.
8.4.2    In the case where the inspection performed by THE PURCHASER indicates that the Products are damaged, defective or short in quantity, THE PURCHASER shall, at the time of notifying such non-conformity, provide ESTABLISHMENT, where relevant, with a sample of the damaged or defective Product.
8.4.3    Should ESTABLISHMENT agree with such results, and given that the damages are not the responsibility of the carrier, ESTABLISHMENT shall replace damaged or defective Products or make up shortfalls in the quantity of Products at the earliest possible time.
For the purpose of this clause 8.4.3, ESTABLISHMENT’s liability for delivering Products found to be damaged, defective or short of quantity shall be limited to replacement of the said Products, and only when there is no liability from the carrier and it is not covered by the fright insurance.
Notwithstanding the above, ESTABLISHMENT shall not be liable to replace damaged or defective Product unless such damage or defect in the Product is directly attributable to ESTABLISHMENT (therefore excluding cases such as damage during principal transportation, delays in customs clearing, bad storage conditions in THE PURCHASER warehouse(s) or any other cause beyond the control of ESTABLISHMENT).  ESTABLISHMENT’s liability for damages occurred in transit shall be limited as per the EXW EDC, Incoterms 2000.
8.4.4    In the event that ESTABLISHMENT should not agree with THE PURCHASER that the Product is defective or that ESTABLISHMENT is responsible for the damage, the issue shall be submitted to an independent Third Party designated by mutual agreement whose decision shall be final.  The costs arising from the intervention of the independent Third Party shall be borne by the Party in the wrong.
8.5    THE PURCHASER shall maintain at all times an inventory as needed to supply its doctors and related to the projected net purchases.

-7-

8.6    THE PURCHASER undertakes to handle and store the Products manufactured in accordance with Good Manufacturing Practice (“GMP”) and according storage conditions, described in the exhibits.
8.7    In the event that any Product delivered to THE PURCHASER does not comply with ESTABLISHMENT’s warranty as set forth herein, ESTABLISHMENT hereby undertakes to replace such non-complying Product at its sole expense.
8.8    THE PURCHASER undertakes to distribute and employ the Products in conformity with the “FEFO - First Expiry - First Out” principle.  THE PURCHASER agrees to be sole responsible of obsolete Products.  ESTABLISHMENT will never ship, as part of the Products, medical devices with an expiry date less than twelve (12) months away from the shipping date.
8.9    In the event that there is a shortage of the Products for whatever reason, ESTABLISHMENT shall apportion supplies of the Products as it sees fit.  ESTABLISHMENT shall use its reasonable endeavours to meet the delivery date specified in that order but time shall not be of the essence of this Agreement and, for the avoidance of doubt, ESTABLISHMENT shall not be liable to THE PURCHASER for any late delivery or non-delivery of the Products, as long as the delay is justified and not longer than 30 (thirty) days, under the penalty of incurring in loss and damages.  Quantities not delivered as a consequence of a shortage shall be considered for the calculation of the Minimum Net Purchase.
8.10    All orders placed by THE PURCHASER in respect of the Products shall be either made in writing and sent to ESTABLISHMENT at an address specified by it from time to time or sent by electronic ordering if requested by ESTABLISHMENT and shall fall in line with the forecasts provided by THE PURCHASER
8.11    Any and all expenses, costs and charges incurred by THE PURCHASER in the performance of its obligations under this Agreement shall be paid by THE PURCHASER.
8.12    THE PURCHASER shall not be entitled by reason of any set-off, counter claim, abatement, or other similar deduction to withhold payment of any amount due to ESTABLISHMENT.
8.13    THE PURCHASER shall be responsible for the collection, remittance and payment of any or all taxes, charges, levies, assessments and other fees of any kind imposed by any governmental of other authority in respect of the purchase, importation, or sale of the Products.
8.14    All prices of the Products are exclusive of any applicable value added or any other sales tax for which THE PURCHASER may be additionally liable.

-8-

8.15    If THE PURCHASER fails to pay any sums due to ESTABLISHMENT under this Agreement as they fall due, ESTABLISHMENT shall be entitled (without prejudice to any other right or remedy it may have) to:
8.15.1    Cancel or suspend any further delivery to THE PURCHASER under any order;
8.15.2    Charge THE PURCHASER interest on the outstanding sum at the rate of 4% of the total amount of the invoice concerned per month of delay, from the date the payment became due until actual payment is made, irrespective of whether the date of payment is before or after any judgement or award in respect of the same.
ARTICLE 9 –FORECAST
9.1    Upon the signature of the Agreement, THE PURCHASER shall provide ESTABLISHMENT with a written forecast containing those monthly quantities of Products that will presumably be ordered by THE PURCHASER and covering a period of twelve (12) months starting from the date of launch of the Products.
Every months, THE PURCHASER shall provide ESTABLISHMENT with a written revised forecast of its monthly requirements of Products for the period covering the next twelve (12) months.
Each order to be issued by THE PURCHASER shall be within the range of twenty per cent (20%) of its last forecast for the same time period.
9.2    Notwithstanding the foregoing, should THE PURCHASER require delivery of Products in excess of twenty per cent (20%) above those quantities stated in its last forecast for the same time period, ESTABLISHMENT agrees to use reasonable efforts to supply such additional quantities.
ARTICLE 10 –MATERIOVIGILANCE
THE PURCHASER shall keep ESTABLISHMENT informed on all reports of adverse events reactions coming from their knowledge with regard to the Products, regardless of their origin – the term « reports » shall also include publications.
Reports on such adverse reactions, which according to the informing party’s professional evaluation may negatively affect the benefit-risk ratio of the Product or may have consequences regarding the Product information (eg labelling, data sheets, package inserts) or may require immediate safety measures (such as special information / warnings to health professionals, patients, authorities or product withdrawal) shall be forwarded to the other Party without delay after becoming known.

-9-

Exchange of materiovigilance information shall be addressed to :
For ESTABLISHMENT :
Quality, Regulatory and Materiovigilance Department: 
		
	Name company :
	ESTABLISHMENT LABS S.A.

		
	Address:
	Bldg. 15, 4th St. Zona Franca Coyol  

Alajuela, Costa Rica 
20113
		
	Phone : Fax :
	+(506).2434.2400 

+(506).2434.2450
For THE PURCHASER : as indicated in the Data Sheet.
Or to such other address for each Party as may be notified from time to time.
ARTICLE 11 –PRODUCT RECALLS
If either Party determines that an event, incident or circumstance has occurred which may result in the need for a “recall” or “market withdrawal” (collectively referred to as “Recall”) of any Product used by THE PURCHASER, such Party shall advise and consult with the other Party regarding such event as set forth below:
11.1    Recall due to breach by THE PURCHASER
To the extent that the Recall of the Product is due to THE PURCHASER’s negligence or wilful misconduct, THE PURCHASER shall bear all out-of pocket costs and expenses of such Recall, including out-of-pocket costs incurred by Third Parties, the out-of-pocket costs of notifying customers and the out-of-pocket costs associated with shipment of such recalled Product and the costs and expenses of the necessary replacement and destruction of such Product which is removed from the market (the “Recall Expenses”).
11.2    Recall due to breach by ESTABLISHMENT
To the extent that the Recall is due to acts or conduct by ESTABLISHMENT, ESTABLISHMENT shall be responsible for the Recall Expenses.
11.3    Recall instituted by the Health Authorities of the Territory
In the event of a compulsory Recall at the behest of a Health Authority of the Territory there shall be no requirement for the Parties to agree on the need for such a Recall.  The Parties shall however co-operate fully with one another in relation to such a Recall and the Recall Expenses shall be borne by the Parties in accordance with clauses 14.1 and 14.2 above.

-10-

11.4    Procedure
Product recalls will be conducted in accordance with THE PURCHASER’s standard operating procedure on recalls which procedure shall be transmitted to ESTABLISHMENT at the latest on the Effective Date of the Agreement.
ARTICLE 12 –TERMINATION
12.1    This Agreement is entered into by ESTABLISHMENT in consideration of THE PURCHASER’s legal and financial situation on the Effective Date of this Agreement.
Consequently, any substantial modification of the situation, status or control of THE PURCHASER will have to be notified to ESTABLISHMENT within thirty (30) days from the date of such substantial modification, and ESTABLISHMENT will then have the right to terminate this Agreement upon a further sixty (60) days’ notice to THE PURCHASER.
In the absence of notification by THE PURCHASER, ESTABLISHMENT shall be entitled to exercise its right to terminate the Agreement as aforesaid whenever it has received sufficient evidence (through publication in media or otherwise) that THE PURCHASER’s situation, status or control has been substantially modified.
For purposes of this Agreement, the term “control” shall mean the power, directly or indirectly, to direct the management and / or policies of THE PURCHASER, whether through the ownership of voting share, by contract, by operation of law or otherwise.
12.2    This Agreement will terminate automatically without any prior notice nor indemnity to any Party in the event any proceeding is commenced by or against THE PURCHASER, seeking relief under any bankruptcy or insolvency law and if such proceeding be involuntary, it remains un-dismissed for thirty (30) days from the date of its filing by the competent authorities.
12.3    In the event that either Party shall violate any provisions of this Agreement, or shall default in the performance of any of its obligations hereunder, including the payment of any invoice on or before its agreed due-time according to the conditions set in the Data Sheet or anywhere else in this Agreement, the non-defaulting Party may, at its sole option, terminate this Agreement by giving written notice to the defaulting Party specifying said default and its intention to terminate and, unless said default shall be rectified by the defaulting Party within thirty (30) days of the notice given, this Agreement shall become terminated thirty (30) days after said notice is given, without any further notice.
12.4    The present Agreement may be terminated by either Party in case of Recall (as defined in this agreement) of the Product from the market due to a decision by the competent Health Authorities of such country.

-11-

The said termination shall not become effective until ten (10) days after dispatch by the terminating Party of a registered letter with receipt explaining the reasons for the letter, to which a copy of the decision of the authorities is to be attached.
12.5    ESTABLISHMENT also reserves the right to terminate the present Agreement if it decides to stop the marketing of any of the Product(s) in the country where THE PURCHASER is located.
The said termination shall not become effective until thirty (30) days following dispatch by ESTABLISHMENT of a registered letter with receipt explaining its decision.
12.6    In case of non compliance during any Commercial Year with any of the Minimum Net Purchases figures as indicated above for two consecutive quarters, the parties shall have a meeting within the next thirty days to negotiate new prices for the products, since the prices granted in the agreement to PURCHASER are based on the volume agreed as minimum purchases.  If the Parties don’t meet or cannot reach an agreement, ESTABLISHMENT may continue charging its regular list prices for the Products on the following orders.
ARTICLE 13 –CONSEQUENCES OF EXPIRATION OR OF TERMINATION
13.1    Expiry of the term or termination of this Agreement by either Party, shall not relieve the Parties hereto of any obligation accruing prior to such termination.
13.2    Neither Party shall be entitled to receive any indemnity or other compensation merely because this Agreement is not renewed beyond the original term or any renewal period.
13.3    Upon the expiry of the term or termination of this Agreement, whatever the cause and the date may be, THE PURCHASER agrees to cease all use of the Trademark(s) and ESTABLISHMENT Logo.
ARTICLE 14 –TRANSFER OF RIGHTS
The rights and obligations of THE PURCHASER under this Agreement, shall not be assignable or be sub-licensed except with the prior written consent of ESTABLISHMENT.
The supply obligations of ESTABLISHMENT shall-be fulfilled by its local distributor: Aesthetic Healthcare Ltd.  If for any reason Aesthetic Healthcare Ltd. stops being the local distributor of ESTABLISHMENT or becomes unable to comply with its obligations, ESTABLISHMENT shall comply with the supply obligations directly, including claims.  All warranty obligations shall be kept at all times by ESTABLISHMENT, except for the submittal and reception of documents, all of which shall be transferred to the local distributor.

-12-

ARTICLE 15 –GENERAL PROVISIONS
15.1    Independent Contractor
For the performance of this Agreement, THE PURCHASER will act as an independent contractor and not as an agent or representative of ESTABLISHMENT.
15.2    Product liability
(a)    ESTABLISHMENT warrants that all Products delivered and sold to THE PURCHASER will be free from defects in material and workmanship at the time of delivery to THE PURCHASER.  This warranty shall be effective per Product for the remaining shelf life of the Product.
(b)    ESTABLISHMENT shall be responsible for, and shall indemnify and hold THE PURCHASER harmless from and against any damage, loss, cost or expense arising out of the claims made by final consumers of the Products in relation to defects in material or workmanship, insofar as these damages are not attributable to faulty handling of the Products by THE PURCHASER.
THE PURCHASER undertakes to inform ESTABLISHMENT of any such claims made by final consumers and not to take any action with respect thereto without ESTABLISHMENT’s prior written consent.
(c)    All other guarantees, warranties, conditions and representations, either express or implied, whether arising under any statute, law, commercial usage or otherwise, including implied warranties of merchantability and fitness for a particular purpose relating to the Products, are hereby excluded to the fullest extent permitted by law.
Furthermore, under no circumstances shall ESTABLISHMENT be liable to THE PURCHASER for any indirect or consequential loss suffered or incurred by THE PURCHASER, howsoever arising.
(d)    THE PURCHASER shall not make any warranties or representations with respect to the Products on behalf of ESTABLISHMENT except to the extent specifically provided in paragraph (b) above or to the extent of the product warranty for final users as published in ESTABLISHMENT website current at the time of purchase.
THE PURCHASER shall indemnify and hold ESTABLISHMENT harmless from all claims and damages, including attorney’s fees, resulting from THE PURCHASER’s violation of this provision of this Agreement.
(e)    THE PURCHASER shall be responsible for, and shall indemnify and hold ESTABLISHMENT harmless from and against any damage, loss, cost or expense relating to Third Party claims or suits arising from the handling, storage, promotion and use of the Products unless such damages, loss, cost or expense is attributable to the Products supplied by ESTABLISHMENT, their properties and/or characteristics and/or any defect therein or non-

-13-

compliance thereof with the relevant regulations in the country of the PURCHASER, and PROVIDING THAT upon receipt of notice by ESTABLISHMENT of any claims or suits, ESTABLISHMENT shall immediately notify THE PURCHASER thereof and at the cost and discretion of THE PURCHASER shall permit THE PURCHASER to handle such claims and suits.
(f)    The Products have a warranty cover provided by ESTABLISHMENT, as indicated in EXHIBIT II hereto.
ARTICLE 16 –NON COMPETITION
For the duration of this Agreement, THE PURCHASER shall use its best efforts not to use and/or promote and/or sell and/or buy, directly or indirectly any other products liable to compete with the Products, as may be permitted by law and local regulations.
ARTICLE 17 –CONFIDENTIALITY
THE PURCHASER agrees to exercise due care to prevent that any confidential information (hereinafter “Information”) about the Products, including the international marketing strategy of ESTABLISHMENT received from ESTABLISHMENT prior or during the term of this Agreement, might be revealed or disclosed to Third Parties.
This obligation to confidentiality shall remain in full force and effect during the whole validity period of the present Agreement plus ten (10) years beginning from its term or termination whatever the cause or the date.  However, the provisions of this Article 20 shall not apply to :
		
	•
	Information which at the time of disclosure, is part of the public knowledge,

		
	•
	Information which after disclosure, becomes part of the public knowledge through no fault of THE PURCHASER or of its employees,

		
	•
	Information which THE PURCHASER can establish by competent proof was in its possession prior to disclosure hereunder and was not acquired from ESTABLISHMENT or ESTABLISHMENT’s Affiliate, directly or indirectly, under a secrecy obligation,

		
	•
	Information which is subsequently obtained lawfully from a Third Party without any secrecy obligation.

ARTICLE 18 –FORCE MAJEURE
Neither THE PURCHASER nor ESTABLISHMENT shall be considered in default or be liable to the other Party for any delay in performance or non-performance caused by circumstances beyond the reasonable control of such Party, including but not limited to explosion, fire, flood, earthquake, war whether declared or not, accident, labour strike or labour disturbances, sabotage, order or decrees of any court or action of governmental authority; 

-14-

provided, however, that diligent efforts are made to resume performance as quickly as possible.  Except as expressly provided elsewhere in this Agreement, if any event of force majeure continues for more than three (3) months, either Party may terminate this Agreement on giving a further three (3) months written notice to the other.
ARTICLE 19 –NOTICES
Any notice required or permitted to be given under this Agreement shall be deemed to have been sufficiently given if delivered personally, by courier or if sent by facsimile, addressed to the Party to be notified, at its address stated in this Agreement or at such other address as may hereafter be furnished in writing to the notifying party, and shall be deemed to have been served at the date of receipt in the case of personal delivery, or four days if delivered by courier and one (1) day after dispatch in the case of facsimile.
ARTICLE 20 –EXHIBITS
20.1    The exhibit I constitutes an integral part of the Agreement and must be respected by THE PURCHASER.
20.2    The said exhibit is as follows:
		
	•
	EXHIBIT I :    LIST OF PRODUCTS AND PRICES

20.3    Given the frequent modifications of the exhibits planned hereafter, it is expressly agreed and understood between the Parties that the modified exhibits will come into effect as soon as they will be validly signed by the representatives of both Parties, regardless of the signature of a written amendment.
ARTICLE 21 –APPLICABLE LAW AND ARBITRATION
This Agreement shall be construed and the rights of the Parties hereto, shall be determined in accordance with the laws of Costa Rica.
All disputes or differences that could relate to, or derived from this Agreement, its execution, liquidation or interpretation; will be resolved in accordance with the following procedure: 1) The Parties shall be subject to mediation mechanism in accordance with the Rules of Mediation of the London Court of International Arbitration.  If, within fifteen (15) working days from the request for mediation, the Parties have not reached a settlement agreement, the dispute or difference shall be settled by, 2) Arbitration in accordance with the Arbitration Rules of that Centre, whose rules the parties submit unconditionally.  The Arbitral Tribunal shall consist of one (1) member, and must decide based on the law.  The London Court of International Arbitration will be the institution responsible for administering the arbitration process.
ARTICLE 22 –ELECTION OF DOMICILE
The Parties declare that they have elected domicile at their offices, as indicated in this Agreement.

-15-

ARTICLE 23 –COMPLETE AND FINAL UNDERSTANDING
23.1    This Agreement represents the complete and final understanding of the Parties hereto and replaces and supersedes all previously existing agreements and arrangements between the Parties hereto relating to the subject matter hereof.
23.2    This Agreement may not be changed orally but any and all modifications to this Agreement shall be made in writing and be subject of appropriate addenda.
23.3    Moreover, it is understood that in the event that any provision of this Agreement is declared void or unenforceable by a court or tribunal of competent jurisdiction, the other provisions hereof not so declared shall remain in full force and effect.
IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly appointed representatives in two (2) original copies.
On the execution date indicated in the Data Sheet.
	
		
	ESTABLISHMENT
	THE PURCHASER

	 
	 

	/s/ Juan Jose Chacon Quiros
	/s/ David Ross

	 
	 

	Director and CEO
	CEO

-16-

EXHIBIT I
LIST OF PRODUCTS AND PRICES
“MOTIVA IMPLANT MATRIX®” products:
See attached.
EXHIBIT II
PRODUCT WARRANTY
See attached.
	
		
	ESTABLISHMENT
	THE PURCHASER

	 
	 

	 
	 

	/s/ Juan Jose Chacon Quiros
	/s/ David Ross

	 
	 

	Director and CEO
	CEO

		
	•
	Special Commercial Conditions:

		
	◦
	The Products will be covered by the normal end-user warranty covering ten years from the implantation date.  The current Product Replacement Policy shall be applicable for BAKER GRADE III or IV Capsular Contracture.

		
	◦
	Initial prices for the current products shall be:

		
	•
	SilkSurface Implants: £100 per unit.

		
	•
	VelvetSurface Implants: £108 per unit.

		
	•
	SilkSurface PLUS Implants: £108 per unit.

		
	•
	VelvetSurface PLUS Implants: £118 per unit.

		
	•
	SilkSurface Implants with QidTM: £106 per unit.

		
	•
	VelvetSurface Implants with OidTM: £114 per unit.

		
	•
	SilkSurface PLUS Implants with QidTM: £114 per unit.

		
	•
	VelvetSurface PLUS Implants with QidTM: £124 per unit.

		
	•
	Ergonomix Round QidTM: £138 per unit.

		
	•
	The price of all the implants includes the Real Warranty.

		
	•
	DISTRIBUTOR may purchase up to 12% (twelve percent) of the total quarterly purchases consisting of implants with a volume equal or higher to 700cc (seven hundred cubic centimeters).  Any additional implants of 700cc or higher volume shall be purchased at regular incremental prices.

	
		
	•
Execution Date: 
	April 7th, 2014

    
	
			
	ESTABLISHMENT
	 
	THE PURCHASER

	 
	 
	 

	/s/ Juan Jose Chacon Quiros
	 
	/s/ David Ross

SUPPLY AGREEMENT
DATA SHEET

		
	•
	PURCHASER: The Hospital Group Healthcare Ltd, a corporation organized under the laws of the United Kingdom having its registered office located in Stoney Lane, Bromsgrove, Birmingham, Worcestershire, B60 1LY, United Kingdom.

		
	•
	Represented by David Ross, CEO.

		
	•
	PURCHASER ADDRESS: Stoney Lane, Bromsgrove, Birmingham, Worcestershire, B60 1LY, United Kingdom.

		
	•
	PURCHASER WAREHOUSE: To be indicated before the Effective Date.

		
	•
	Effective Date: March 1st, 2014.

		
	•
	Credit term for invoiced amounts: 60 days.

		
	•
	Prices: Indicated in Exhibit D of the Supply Agreement

		
	•
	Final Date: three years after signature.

		
	•
	Minimum Net Purchases for the first 3 years shall be:

	
		
	Period
	TOTAL

	First
Commercial
Year
	3,000

	Second
Commercial
Year
	4,000

	Third
Commercial
Year
	5,000

		
	•
	CREDIT LIMIT: £200,000

		
	•
	Exchange of materiovigilance information shall be addressed for THE PURCHASER:

Name of the company: The Hospital Group Healthcare Ltd.
Attn: David Ross, CEO.
Address: Stoney Lane, Bromsgrove, Birmingham, Worcestershire, B60 1LY, United Kingdom
	
		
	Phone: 
	 

	Email: 
	 

		
	•
	Special Commercial Conditions:

		
	◦
	The Products will be covered by the normal end-user warranty covering ten years from the implantation date.  The current Product Replacement Policy shall be applicable for BAKER GRADE III or IV Capsular Contracture.

		
	◦
	Initial prices for the current products shall be:

		
	•
	SilkSurface Implants: [***].

		
	•
	VelvetSurface Implants: [***].

		
	•
	SilkSurface PLUS Implants: [***].

		
	•
	VelvetSurface PLUS Implants: [***].

		
	•
	SilkSurface Implants with QidTM: [***].

		
	•
	VelvetSurface Implants with OidTM: [***].

		
	•
	SilkSurface PLUS Implants with QidTM: [***].

		
	•
	VelvetSurface PLUS Implants with QidTM: [***].

		
	•
	Ergonomix Round QidTM: [***].

		
	•
	The price of all the implants includes the Real Warranty.

		
	•
	DISTRIBUTOR may purchase up to [***] of the total quarterly purchases consisting of implants with a volume equal or higher to 700cc (seven hundred cubic centimeters).  Any additional implants of 700cc or higher volume shall be purchased at regular incremental prices.

	
		
	•
Execution Date: 
	April 7th, 2014

	
			
	ESTABLISHMENT
	 
	THE PURCHASER

	 
	 
	 

	/s/ Juan Jose Chacon Quiros
	 
	/s/ David RossExhibit 10.3

 

EXCLUSIVE LICENSE AGREEMENT

 

THIS EXCLUSIVE LICENSE
AGREEMENT, dated April 10, 2017, (the “Effective Date”) by and between World Media & Technology Corp., a Nevada
corporation with corporate headquarters located at 600 Brickell Ave., Suite 1775, Miami, Florida 33131 (“WRMT”
or the “Licensee”) and Giner, Inc., incorporated in the state
of Massachusetts whose corporate office is located at 89 Rumford Ave., Newton, MA 02466 (“GI” or the “Licensor”).
Each a “Party” and collectively the “Parties,” agree as follows:

 

RECITALS

 

WHEREAS, GI is
a research and development orientated company, currently producing some 10,000 alcohol sensors per annum based on patented technology;
GI has developed a miniaturized transdermal alcohol sensor (the “TAS”); and

 

WHEREAS, WRMT has
an established route to consumer markets, and seeks to incorporate the TAS into WRMT’s Helo product and distribute it to
the consumer self-monitoring market; and

 

WHEREAS, GI
is the legal and beneficial owner of the TAS and its related Intellectual Property Rights as further described in Appendix B, attached
hereto and incorporated herein (together, the “Licensed Products”) and is willing to license these Licensed Products
exclusively to WRMT in a limited field on the terms set out in this License.

 

Now,
Therefore, the Parties have reached the following agreement with respect to the License:

 

AGREEMENT

 

		1	INTERPRETATION:

 

		1.1	The definitions and rules of interpretation in this clause apply in this License.

 

	“Affiliate”	
        Means, as it relates to WRMT,
        World Global Network, and any corporation or other business entity controlled by or in common control of a party. "Control"
        as used herein means ownership directly or through one or more Affiliates, of 55% or more of the shares of the share capital entitled
        to vote for the election of directors, in the case of any corporation, or 55% or more of the equity interests in the case of any
        other type of legal entity, status as a general partner in any partnership, or any other arrangement whereby a party controls or
        has the right to control the board of directors or equivalent governing body of a corporation or other entity.

         

	“Big Data”	
        means any data
        outputs provided by GI’s Advanced App, including, but not limited to, user data for those users that consent to the use of
        their data, alcohol sensor raw signals, alcohol sensor converted signals, and any advanced algorithms outputs.

         

  

    	 	1	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

	“Documentation” 	means any written materials supplied by Licensor, either in print or digital format, to be used in conjunction with the Licensed Products for purposes including, but not limited to, installation, operation, training, demonstration, and maintenance of the Licensed Products.

                                                                                 

	“Integrated Product”	means the alcohol monitoring device that is manufactured by WRMT, or a third party on its behalf, sometimes referred to herein as the “Helo or Helo 2.0 device or unit”, that contains the TAS unit supplied by GI, the TAS housing and the circuits and controls supplied by WRMT.

                                                                            

	“Intellectual Property Rights” or “IPR”	
        all patents, copyrights, design
        rights, trademarks, service marks, trade secrets, know-how, database rights and other rights in the nature of intellectual property
        rights (whether registered or unregistered) and all applications for the same, anywhere in the world; (ii) rights relating to innovations,
        know-how, trade secrets and confidential, technical and non-technical information; (iii) moral rights, mask work rights, author's
        rights, and rights of publicity; and (iv) other industrial, proprietary and intellectual property related rights (of every kind
        and nature throughout the world however designated and whether arising by operation of law, contract, license, or otherwise) and
        all registrations, initial applications, renewals, extensions, continuations, divisions, or reissues now or hereafter in force
        (including any rights in the foregoing) arising anywhere in the world, that exist as of the Effective Date or hereafter come into
        existence, regardless of whether or not such rights have been registered in jurisdictions in accordance with the relevant legislation.

         

	“TAS unit”	means the transdermal alcohol sensing component without the sensor housing or sensor housing stack-up.

 

		1.2	The headings in this License do not affect its interpretation.
Save where the context otherwise requires, references to clauses and schedules are to clauses and schedules of this License.

 

		1.3	Unless the context otherwise requires:

 

		1.3.1	references to statutory provisions include those statutory
provisions as amended or re-enacted; and

 

		1.3.2	references to any gender include all genders.

 

		1.4	In the case of conflict or ambiguity between any provision
contained in the body of this License and any provision contained in the Schedule or appendices, the provision in the body of
this License shall take precedence.

 

		1.5	Words in the singular include the plural and in the plural
include the singular.

 

    	 	2	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		2	EXCLUSIVE LICENSE AGREEMENT AND TERM

 

		2.1	Licensor hereby grants to the Licensee and its Affiliates,
from the Effective Date and during the Term:

 

		(a)	a world-wide, non-exclusive, license to operate, use,
integrate and display the Licensed Products; and

 

		(b)	a world-wide, exclusive license to use, market, sell
and distribute the Licensed Products solely (i) as contained in the Integrated Product, and (ii) in the consumer self-monitoring
market.

 

		(i)	Market sectors not covered by the worldwide exclusive
license granted to WRMT include the alcohol treatment market, the law enforcement market, the professionals monitoring market,
the automotive market, and the academic research market. If a third-party purchaser of Helo devices begins selling in one of the
excluded markets, WRMT will immediately inform GI upon knowledge of third-party purchaser entry into one of the excluded markets,
and WRMT may continue selling Helo devices to the third-party purchaser only upon consent from GI.

 

		2.2	GI agrees to provide WRMT with a minimum of one hundred
(100) TAS units for WRMT field testing by no later than July 1st, 2017, or one month from the date that WRMT’s
design partners finalize the TAS design for integration into their Helo 2.0 alpha unit, whichever comes later.

 

		2.3	Within five (5) days of the Effective Date, GI shall
provide a demonstration to WRMT of GI’s transdermal alcohol sensing capability by: (a) using the GI R&D prototype WrisTAS
7 device for self-monitoring of drinking events, or (b) a video or in-person demonstration of the GI miniaturized “waterless”
prototype transdermal alcohol sensor at GI’s lab.

 

		2.4	Licensor hereby agrees to provide Licensee with: (a)
all updates, enhancements, and upgrades to the Licensed Products, as and when made generally available by Licensor, and (b) the
technical maintenance and support services as identified in Appendix D for the Term of the Agreement.

 

		3	CONSIDERATION

 

		3.1	NRE Funding.

 

		a)	WRMT, or a third party acceptable to GI, such approval
not to be unreasonably withheld, agrees to fund the non-recurring engineering (“NRE”) costs according to the payment
schedule as set forth in Appendix C1. GI’s approval of a third party to provide funding of the NRE will not relieve WRMT
of its obligation to make the NRE funding payments set forth herein, and any failure of the third party to provide such funding
shall constitute a breach of this Agreement by WRMT.

 

		b)	The initial outline of the NRE project milestones and
subtasks are provided in the Appendix A Gantt chart, which will be updated monthly, upon mutual written consent of both parties,
as the milestones and subtasks are completed or modified according to the project progression.

 

    	 	3	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		c)	GI will apply the revenue received Sensor Enablement Fee (Section 3.5) and the GI Advanced App Payments
(Section 3.6) against the NRE cost up to a total of 50% of the total NRE cost. If GI enters one of the excluded markets (Section
2.1) with sales of TAS units that are the same or materially similar to the ion exchange membrane-based electrochemical TAS units
developed under this NRE, GI will reimburse WRMT up to an additional 25% of the total NRE cost also paid back by the Sensor Enablement
Fee and GI Advanced App Payments.

 

		d)	For the duration of the NRE, GI will provide WRMT with a monthly update on funds spent for GI internal
R&D and for the automation system, including tasks accomplished during each monthly period. GI will also allow a third-party
auditor to examine the NRE expenditures upon WRMT’s request. If, following an audit of Licensor’s records, it is determined
that Licensor has materially overcharged WRMT, Licensor will promptly refund or credit WRMT’s account any excess amounts
and will reimburse WRMT for any external auditor fees incurred by WRMT in its audit of Licensor’s records if WRMT has cause
to audit Licensor. Any amounts that are billed in advance of a projected payment shall not constitute an overcharge. Licensor agrees
to provide and agrees to require that its subcontractors and agents provide WRMT and its auditor’s access to such records.
GI must notify WRMT in advance of any potential increase in NRE costs provided in Appendix C1, and if such an increase is accepted
by WRMT in writing, then WRMT will pay the additional costs upfront up to a maximum of $160,000, and GI will fully reimburse
WRMT for those additional costs from the revenue generated by the Sensor Enablement Fee (Section 3.5) and the GI Advanced App Payments
(Section 3.6). GI will pay any NRE increase beyond $160,000.

 

		e)	WRMT will have the right to terminate the Agreement at the three (3), six (6), or nine (9) month payment
dates, wherein all rights and obligations of the both Parties, including without limitation all licenses granted hereunder, will
be terminated subject to the terms of this Agreement. However, obligations and rights under this Agreement or attached Appendix,
which by their nature would reasonably continue beyond the Termination or expiration of this Agreement or Appendix (including those
in the Sections entitled “Confidentiality” “Indemnification,” “Infringement,” and “Representations
and Warranties”) will survive the Termination or expiration of this Agreement. Without limiting the foregoing, in the event
of any such termination WRMT shall be obligated to pay GI for all NRE costs and expenses incurred prior to the date of such termination,
to the extent not covered by the prior monthly payments.

 

		f)	If GI does not receive payment within 10 days of the three (3), six (6), or nine (9) month payment
dates, Giner will issue a notice of non-payment and WRMT will have 20 days to make payment from the date the notice was issued.
If the 20-day period has expired without payment from WRMT, GI has the right to stop work on the NRE and will not be held liable
for any damages, including special, consequential, or punitive damages, due to delay(s) resulting from WRMT’s NRE non-payment.
GI will have the right to collect any funds spent before the stoppage of work due to non-payment and not covered by previous NRE
payments. The rights set forth in this Section are in addition to the termination rights set forth in Section 7 below.

 

    	 	4	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		3.2	WRMT agrees to buy transdermal alcohol sensors exclusively
from GI according to the payment conditions set forth in this Section. WRMT will have the right to buy an alternative transdermal
alcohol sensor (“Alternative TAS”) technology that is not materially the same or similar to GI’s ion exchange
membrane based TAS unit offered on the market at a lesser unit price. GI will have the right of first refusal to match the price
of the Alternative TAS, as follows:

 

		a)	In the event that WRMT proposes to purchase an Alternative TAS (a “Proposed Transaction”),
then WRMT shall send to GI a notice in writing of all of the terms of the Proposed Transaction (such notice, the “Offer
Notice”). The Offer Notice shall constitute an irrevocable offer of the Alternative TAS which is the subject of the Proposed
Transaction (the “Offered Alternative Work”) to GI, on the basis described in the Proposed Transaction.

 

		b)	At any time within thirty (30) business days after receipt by GI of the Offer Notice (the “Option
Period”), GI may elect to accept the offer with respect to any or all of the Offered Alternative Work under identical
terms of the Proposed Transaction and shall give written notice of such election (the “Acceptance Notice”) to
WRMT within the Option Period. The closing for any of the Offered Alternative Work by GI shall take place within thirty (30) days
following the expiration of the Option Period. After the expiration of the Option Period, if GI has not provided to WRMT an Acceptance
Notice for any or all of the Offered Alternative Work under identical terms of the Proposed Transaction, then WRMT may purchase
such Offered Alternative Work on identical terms from third parties. However, in the course of negotiation with third parties,
if the terms of the Proposed Transaction are materially modified, then WRMT shall again send an Offer Notice to GI outlining any
such material modification of the Proposed Transaction (the “Revised Transaction”) and shall grant GI a new Offering
Period in which to accept such Revised Transaction. If GI does not elect to accept the offer, then all rights and obligations under
this Agreement shall terminate in accordance with Section 7.4. However, obligations and rights under this Agreement or attached
Appendix, which by their nature would reasonably continue beyond the Termination or expiration of this Agreement or Appendix (including
those in the Sections entitled “Consideration”, “Payment”, “Confidentiality” “Indemnification,”
“Infringement,” and “Representations and Warranties”) will survive the Termination or expiration of this
Agreement.

 

		3.3	Per Unit Pricing. WRMT agrees to pay GI a unit cost for
each unit TAS sold to WRMT according to an annual volume-based sliding unit scale as set forth in Appendix C2.

 

		3.4	Minimum Volume Requirements.
WRMT hereby guarantees that the aggregate amount of TAS units purchased by WRMT from GI under this Agreement during each of Year
1, 2, 3, 4 and Year 5, commencing January 1, 2018, or an earlier date if applicable, shall equal or exceed the amounts as set
forth in Appendix C3, attached hereto.

 

		a)	If WRMT should fail to meet the yearly volume requirements, WRMT may retain exclusivity by paying
One Dollar ($1.00) per TAS unit for the number of shortfall units not purchased in a given year.

 

		b)	In the event WRMT fails to meet the minimum volume requirements set forth in Appendix C3 and fails
to pay the shortfall amount within 45 days from the end of the applicable year period, then, notwithstanding anything in this Agreement
to the contrary, and at GI’s election and not obligation, (i) GI shall be free to appoint other distributors for its TAS
units in the consumer self-monitoring market, (ii) WRMT’s exclusive rights to the sale, marketing, and distribution of Licensed
Products shall become non-exclusive, and (iii) GI will have the right to exclusively license the Licensed Products for sale, marketing,
and distribution in the consumer self-monitoring market (and this Agreement and all licenses granted to WRMT hereunder will terminate)
upon payment to WRMT for 50% of the total NRE amounts actually paid by WRMT less any NRE repayments to WRMT according to the provisions
in Section 3.1.

 

    	 	5	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		3.5	Sensor Enablement Fee.
In lieu of revenue-sharing payments generated by third-party API developers from the use of GI’s transdermal alcohol
sensor software development kit, WRMT will provide an additional sensor enablement fee of $0.25 per sensor for the access to GI’s
transdermal alcohol sensor by third-party apps.

 

		3.6	Giner Advanced App Payments.
GI will receive 30% of the Net Revenue, as defined in Appendix F, generated by purchases, downloads or subscriptions of the advanced
app developed by GI under the terms set forth in Section 4.3.

 

		4	WORK; ACCEPTANCE

 

		4.1	Labor and Materials. GI will furnish all supervision,
labor, tools, power, transportation, material and supplies (collectively, the “Labor and Material”) specified
in the applicable Statement of Work (“SOW”) except any items specifically listed in an Appendix E as being furnished
by WRMT or others. It is GI’s duty to inspect all Labor and Material furnished by GI in connection with the Services rendered
as part of the NRE (Appendix D), and to report all defects of which GI becomes aware in the performance of the Services. Such
inspection will include inspection for defects that could cause property damage or personal injury. GI will not use any Labor
and Material, or permit the same to be incorporated into the Services, which is defective or which would otherwise result in an
unreasonable risk of harm to persons or property.

 

		4.2	GI shall perform the integration work as set forth in
the Statement of Work (“SOW”) as set forth in Appendix E, and provide the deliverables to WRMT specified therein.

 

		a)	WRMT shall be the exclusive owner of all right, title,
and interest in and to all the “Integration Work,” consisting solely of the Intellectual Property Rights related to
the TAS housing design and specific electronic circuit layout (but not the electronic circuit schematic that is the subject of
GI’s background intellectual property) that are integrated with the Helo device. Licensor hereby agrees to assign or have
assigned to WRMT and hereby assigns all Intellectual Property Rights in and to the Integration Work. GI and WRMT agree to negotiate
in good faith for the sale of the TAS housings to GI that are subject to the rights granted for the Integration Work.

 

		4.3	GI agrees to build a mobile software application using
TAS and other Helo data, and this application shall have advanced features, such as a hangover alert, as set forth in more detail
in the Statement of Work Appendix F (the “Advanced App”).

 

    	 	6	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		a)	GI shall be the exclusive owner of all right, title,
and interest in and to the Advanced App, including, without limitation, all Intellectual Property Rights related thereto. Notwithstanding
the foregoing, WRMT retains the rights to any data stored in, or generated through, the use of the Advanced App; see Section 6.3
below.

 

		4.4	Acceptance Procedure

 

		a)	Upon receipt of the Licensed Products and/or any other
deliverables specifically contemplated by this Agreement, as applicable (each, a “Deliverable” and together, the “Deliverables”),
WRMT will have thirty (30) business days from the date of receipt (“Acceptance Period”) in which to test and evaluate
the Deliverable as specified in this Agreement, and determine whether it materially conforms to the Specifications. Before the
end of the Acceptance Period, WRMT will provide GI with a written notice of acceptance of the Deliverable or a notice of rejection
that (i) specifies in reasonable detail the material non-conformance(s) to the applicable Specifications that are the basis for
the rejection, and (ii) is accompanied by test suites and test results, if applicable, evidencing such non-conformance(s). A failure
of a Deliverable to operate in accordance with the applicable Specifications that is caused by other materials or devices, not
supplied by GI, in which the Deliverable is integrated shall not constitute a failure of the Deliverable itself and shall not
be grounds for rejection of the Deliverable. If GI does not receive such a notice of rejection during the Acceptance Period, the
Deliverable will be deemed accepted.

 

		b)	If GI receives such a notice of rejection during the
Acceptance Period, GI will use its best efforts to correct any material non-conformance(s) specified in the rejection notice and
to deliver the corrected Deliverables Item to WRMT. The process set forth in this Section will continue until one of two events
occur: (a) the Deliverables are accepted by WRMT; or (b) if (30) thirty business days after GI received the notice of rejection
have passed without a response from GI, then Deliverables Item will be deemed not accepted. If (b) occurs, WRMT shall not be liable
for any of the work performed by GI and shall be entitled to a refund of all monies previously paid for that particular Deliverables
Item.

 

		4.5	WRMT will provide GI with any assistance and grant GI
access to any information, subject to the confidentiality provisions set forth in this Agreement, GI requires to permit GI to
bring the Deliverables to functionality described in the Appendices, the Specifications in the SOW and elsewhere. WRMT will ensure
that all WRMT’s personnel who may be necessary or appropriate for the successful development, testing, and/or implementation
of the Deliverable on reasonable notice, (i) be available to assist GI’s personnel by answering business, technical and
operational questions and providing requested documents, guidelines, procedures in a timely manner; (ii) participate in progress
related meetings; and (iii) contribute to system testing. WRMT is responsible for the results produced to its business and engineering
requirements. WRMT shall not be liable for any delays in development or implementation of the Deliverables due to lack of assistance
by WRMT or other factors beyond WRMT’s control.

 

		4.6	Shipment; Inspection

 

		a)	Purchase Orders. WRMT shall order TAS units (“Products”)
by written notice to GI. Each order shall specify the number of units to be shipped, the type of units to be shipped, the desired
method of shipment and the location. GI shall indicate its acceptance of such order by returning a signed copy to WRMT. GI agrees
to ship units to WRMT as close as possible to the delivery schedule set forth in each order as accepted by GI, unless GI otherwise
indicates in writing. GI shall not be required to honor any order that specifies a shipping date earlier than that approved in
writing.

 

    	 	7	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		b)	WRMT Inspection; Rejection. WRMT shall inspect all Products promptly upon receipt thereof
and may reject any defective Product, provided that WRMT shall (i) within the earlier of thirty (30) days after receipt of such
alleged defective Product or ten (10) days after discovery of such alleged defect, notify the GI of its rejection and request a
Return Material Authorization (‘RMA’) number and (ii) within ten (10) days of receipt of the RMA number from GI return
such rejected Product to GI, freight prepaid and properly insured. Products not rejected within the foregoing time periods shall
be deemed accepted by WRMT. In the event that GI determines that the returned Product is defective and properly rejected by WRMT,
GI shall at its option, repair or replace such defective Product, or accept return for credit of such defective Product. GI shall
return to WRMT, freight prepaid, all repaired or replaced Products properly rejected by WRMT. In the event that any rejected product
is determined by GI to not be defective or to have been modified or subjected to unusual electrical or physical stress, misuse,
abuse or unauthorized repair, WRMT shall reimburse GI for all costs and expenses related to the inspection, repair, if any, and
return of such Product to WRMT.

 

		c)	Shipment. All shipments of Product shall be made FOB GI’s plant and liability for
loss or damage in transit, or thereafter, shall pass to WRMT upon GI’s delivery of Product to a common carrier for shipment.
Shipping dates are approximate and are based, to a great extent, on prompt receipt by GI of all necessary ordering information
from WRMT. WRMT shall bear all costs of transportation and insurance and will promptly reimburse GI if GI prepays or otherwise
pays for such expenses. GI shall not be in default by reason of any failure in its performance under this Agreement if such failure
results from, whether directly or indirectly, fire, explosion, strike, freight embargo, Act of God or of the public enemy, war,
civil disturbance, act of any government, de jure or de facto, or agency or official thereof, material or labor shortage, transportation
contingencies, unusually severe weather, default of any other manufacturer or a supplier or subcontractor, quarantine, restriction,
epidemic, or catastrophe, lack of timely instructions or essential information from WRMT, or otherwise arisen out of causes beyond
the control of the GI. Nor shall the GI at any time be liable for any incidental, special or consequential damages.

 

		4.7	Payment

 

		a)	GI shall invoice WRMT for each order at WRMT’s address set forth in Section 17 below after
shipment of such order by GI. WRMT shall pay GI net (30) thirty days from GI’s date of invoice. All payments will be made
in U.S. Dollars. WRMT will advise GI of any billing discrepancies or disputes within ten (10) days after receiving the invoice.

 

		b)	In the event GI has not received payment within (30) thirty days and has not been notified of any
billing discrepancies or disputes by WRMT, GI will shall have the right to discontinue manufacturing or supplying any products
to WRMT. The rights set forth in this Section are in addition to the termination rights set forth in Section 7.

 

		c)	The Sensor Enablement Fee will be due and payable upon delivery of the TAS units to WRMT.

 

    	 	8	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

  

		d)	The Advance App Payments shall be payable through WRMT’s payment processor, Paynovi, at the
end of the month following the month in which the Advanced App was downloaded by an end user.

 

		e)	WRMT shall keep, and shall cause any third party payment processor, including Paynovi, to keep
records of all transactions for which payments under the preceding subsections are due hereunder, in sufficient detail to enable
such amounts to be verified, for a period of two (2) years from the date of payment of such fees. WRMT will permit, and shall cause
its third party payment processors, including Paynovi to permit, such records to be inspected by an auditing firm selected by GI
up to twice in each calendar year. All such examinations shall be made at GI’s expense, unless such an examination discloses
an underpayment in excess of 5% of the amount actually due, in which event WRMT shall immediately pay the reasonable costs of such
examination together with the amount due and owing.

 

		5	REPRESENTATIONS AND WARRANTIES

 

		5.1	Authority. Each Party represents and warrants
that (A) it has obtained all necessary approvals, consents and authorizations to enter into this Exclusive License Agreement and
to perform and carry out its obligations under this Exclusive License Agreement; (B) the person executing this Exclusive License
Agreement on the party’s behalf has express authority to do so and to bind the party; (C) the execution, delivery, and performance
of this Exclusive License Agreement does not violate any provision of any bylaw, charter, regulation, or any other governing authority
of the party and is duly authorized by all necessary partnership or corporate action; and (D) this Exclusive License Agreement
is a valid and binding obligation of the party.

 

		5.2	Attached as Schedule 5.4 is a list of any and all companies that have a contract or other licensing
arrangement with GI for the use of GI’s transdermal alcohol sensor technology or related IPR. GI represents and warrants
that it has no existing contracts or licensing agreements with KHN/BACtrack for the use of GI’s transdermal alcohol sensor
technology and related IPR.

 

		5.3	GI hereby represents and warrants that as of the Effective Date it
has ceased all communication with any other interested parties, and shall not solicit any new third parties, regarding its transdermal
alcohol sensor technology in the consumer self-monitoring market. This non-communication period will expire as of August 31, 2017
or at the termination of this Agreement, whichever comes later. During the non-communication period, GI may enter discussions with
third parties only for the excluded markets as listed in Section 2.1(b) above.

 

		5.4	Ownership. Licensor warrants that it owns or has sufficient rights in the Deliverables and
any and all related Intellectual Property Rights to grant WRMT the licenses set forth herein. Licensor warrants that it has and
will comply with all laws attendant upon its performance under this Agreement.

 

    	 	9	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		5.5	Claims or Demands. Licensor represents and warrants, to its knowledge, that there are no
unresolved claims, demands or pending litigation, relating to the Licensed Products or the Intellectual Property Rights in the
Licensed Products. Upon receipt of notice from a third party alleging any claim, including, but not limited to claims arising out
of performance of activities under this Exclusive License Agreement or any infringement or misappropriation of any Intellectual
Property Rights by use or license of Licensed Products, Licensor shall take all appropriate actions to handle the claim in accordance
with the requirements of this Exclusive License Agreement. Licensor will immediately notify WRMT if, during the term of this Agreement,
Licensor becomes aware of any action, suit or proceeding, pending or threatened, which may have a material adverse effect on Licensor’s
ability to fulfill its obligations under this Agreement.

 

		5.6	Warranty of Services. Licensor warrants and represents that the NRE services performed by
Licensor or its personnel shall be performed in a professional manner, in material compliance with the specifications given by
WRMT, consistent with the best practices in Licensor’s industry and in a diligent, workmanlike, and expeditious manner.

 

		5.7	Licensor warrants to WRMT that at the time of delivery to WRMT
the Deliverables furnished hereunder will be free from all liens and encumbrances, and will substantially conform to and perform
in accordance with applicable Specifications and Performance Requirements, set forth in this Agreement. Any Deliverables that fail
to perform in accordance with the applicable Specifications and Performance Requirements at the time of delivery shall be repaired
or replaced by GI, free of charge, provided GI is notified of such failure within thirty (30) days following the date of delivery.
In addition, if a Deliverable contains one or more original equipment manufacturer’s (“OEM”) warranty,
Licensor represents that it has the authority to and does assign such OEM warranties to WRMT. Licensor further warrants
that at the time of delivery to WRMT the Licensed Products will perform and be compatible with the Licensee’s technical environment,
including hardware, operating system(s), software application(s), and networks specified by Licensee in the Specifications set
forth in this Agreement. Licensor warrants that all Deliverables provided to WRMT hereunder will be tested prior to delivery to
WRMT.

 

		5.8	The warranties set forth herein are extended solely to WRMT and WRMT is responsible for all warranties
extended directly to end users of the Integrated Products. WRMT will not provide any warranties with respect to the TSA units integrated
in the Integrated Products that exceed the warranties set forth herein without the prior written consent of GI.

 

		5.9	THE ABOVE ARE THE ONLY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, THAT ARE MADE BY GI AND
GI DISCLAIMS ALL OTHER WARRANTIES, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, TITLE, NON-INFRINGEMENT
AND FITNESS FOR A PARTICULAR PURPOSE. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY GI, ITS AGENTS OR EMPLOYEES SHALL CREATE
A WARRANTY OR IN ANY WAY INCREASE THE SCOPE OF THE WARRANTIES IN THIS AGREEMENT.

 

		5.10	All obligations relating to the sale of an Integrated Product to
an end user customer shall remain with WRMT GI will have no obligations with respect to the warranting of any Integrated
Products, other than as may be expressly set forth in this Section. WRMT will invoice the end user customer for any payments that
may become due from the customer, and WRMT will collect and receive payments from the end user customer on account of any such
invoice.

 

    	 	10	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		6	INTELLECTUAL PROPERTY RIGHTS

 

		6.1	The Licensee acknowledges that all Intellectual Property Rights in the Licensed Products belong
to the Licensor, and the Licensee shall have no rights in or to the Licensed Products other than the right to use it in accordance
with the terms of this License. The Licensor’s Intellectual Property Rights comprise existing intellectual property as of
the Effective Date of this Agreement, including, but is not limited to, US Nonprovisional Patent No. 5,944,661, US Provisional
Patent No. 62/447,214 ,TAS units currently sold to collaborators and commercial partners, the WrisTAS 7 sensing component and all
previous sensing component versions, the WrisTAS 7 device, a miniaturized “waterless” TAS sensing component, potentiostatic
circuitry, electronic circuit layout and design for the TAS sensor, sensor hardware, sensor software, data analysis algorithms,
calibration methods, calibration curves and values, and manufacturing know-how thereof. Licensor’s Intellectual Property
Rights also comprise any future intellectual property developed related to Licensee’s transdermal alcohol sensor technology
developed by Licensee.

 

		6.2	Licensor’s Marks. Licensor grants WRMT the right to use, reproduce, publish and display Licensor’s
names, trademarks, service marks, designs, logos or symbols (“Licensor Marks”), including the Licensed Product names
and Licensor’s Marks, in connection with the development, use, reproduction in promotional and marketing materials, content
directories and indices, and electronic and printed advertising, newsletters and mailings and exhibitions, trade shows or equivalent
events about Licensor and its relationship with WRMT. This Agreement gives WRMT a non-exclusive, royalty-free, limited license
to reproduce Licensor Marks as reasonably necessary for the sole purpose of allowing WRMT to fully promote and market the Licensed
Products pursuant to the terms of this Agreement. WRMT acknowledges and agrees that Licensor is the exclusive owner of Licensor
Marks and that their use as provided in this Agreement will not create in WRMT any right, title or interest therein or to them.

 

		6.3	Notwithstanding the foregoing, the parties agree that the Integration Work and their related IPR,
and any data stored in the Licensed Products, Advanced App or in relation thereto that relates to Licensee’s business or
is generated through end user’s use of the Licensed Products or Advanced APP or is generated in the course of Licensee’s
operations, including any ”Big Data”, or data structures or relationships is the exclusive property of Licensee.

 

		a)	GI will have the right of first refusal to match any
proposal involving the exploitation of “Big Data” generated from GI’s TAS, as follows:

 

		i)	In the event that WRMT proposes to offer “Big Data”
generated from GI’s TAS (a “Proposed Transaction”), then WRMT shall send to GI a notice in writing of
all of the terms of the Proposed Transaction (such notice, the “Offer Notice”). The Offer Notice shall constitute
an irrevocable offer of the Big Data which is the subject of the Proposed Transaction (the “Offered Big Data”)
to GI, on the basis described in the Proposed Transaction.

 

    	 	11	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		ii)	At any time within thirty (30) business days after receipt
by GI of the Offer Notice (the “Option Period”), GI may elect to accept the offer with respect to any or all
of the Offered Big Data under identical terms of the Proposed Transaction and shall give written notice of such election (the
“Acceptance Notice”) to WRMT within the Option Period. The closing for any of the Offered Big Data by GI shall
take place within thirty (30) days following the expiration of the Option Period. After the expiration of the Option Period, if
GI has not provided to WRMT an Acceptance Notice for any or all of the Offered Big Data under identical terms of the Proposed
Transaction, then WRMT may offer such Offered Big Data on identical terms to third parties. However, in the course of negotiation
with third parties, if the terms of the Proposed Transaction are materially modified, then WRMT shall again send an Offer Notice
to GI outlining any such material modification of the Proposed Transaction (the “Revised Transaction”) and shall grant
GI a new Offering Period in which to accept such Revised Transaction.

 

		6.4	WRMT shall have the right of first refusal on a deal
for any GI spin-off to transdermal sensing technology (e.g. a transdermal marijuana sensor, a transdermal carbon dioxide sensor,
etc) (“Derivative Work”), as follows:

 

		a)	In the event that GI proposes to license, sell, assign
or otherwise transfer ownership of Derivative Work (a “Proposed Transaction”), then GI shall send to WRMT a notice
in writing of all of the terms of the Proposed Transaction (such notice, the “Offer Notice”). The Offer Notice shall
constitute an irrevocable offer of the Derivative Work that is the subject of the Proposed Transaction (the “Offered Derivative
Work”) to WRMT, on the basis described in the Proposed Transaction.

 

		b)	At any time within thirty (30) business days after receipt by WRMT of the Offer Notice (the “Option
Period”), WRMT may elect to accept the offer with respect to any or all of the Offered Derivative Work under identical terms
of the Proposed Transaction and shall give written notice of such election (the “Acceptance Notice”) to GI within the
Option Period. The closing for any of the Offered Derivative Work by WRMT shall take place within thirty (30) days following the
expiration of the Option Period. After the expiration of the Option Period, if WRMT has not provided to GI an Acceptance Notice
for any or all of the Offered Derivative Work under identical terms of the Proposed Transaction, then GI may offer such Offered
Derivative Work on substantially similar terms to third parties. However, in the course of negotiation with third parties, if the
terms of the Proposed Transaction are materially modified, then GI shall again send an Offer Notice to WRMT outlining any such
material modification of the Proposed Transaction (the “Revised Transaction”) and shall grant WRMT a new Offering Period
in which to accept such Revised Transaction.

 

		7	TERM, TERMINATION AND RIGHT OF FIRST REFUSAL

 

		7.1	The term of this Agreement shall begin on the Effective
Date and shall continue until December 31, 2022 (the “Initial Term”), subject to perpetual automatic annual renewal,
as follows: If WRMT meets the target volume in Year 5, as set forth in Appendix C3, or maintains exclusivity by paying the shortfall
fee, then the Agreement will automatically renew for an additional year, with a new volume target to be negotiated and mutually
agreed upon by both parties in good faith. The Agreement will continue to automatically renew for subsequent annual periods so
long as WRMT meets or exceeds the volume target of the preceding year or pays the shortfall fee. The target volume of each successive
year after Year 5 shall not exceed an increase of fifteen percent (15%) of the preceding year’s target volume, and such
increase amount shall apply if the parties are not otherwise able to mutually agree on an increase.

 

    	 	12	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		7.2	This Agreement may be terminated by either party if the
other party fails to perform fully, or comply fully, with any material provision of this Agreement and such failure continues
for a period of 30 days after receipt of written notice of such non-conformance or noncompliance.

 

		7.3	At any time following the full payment to GI of the NRE, in the event that WRMT determines Helo
2.0 and successor products using the GI TAS is no longer financially viable, WRMT may terminate this Agreement, and GI will have
the option for a period of eighteen (18) months from date of WRMT’s notice under this provision to buy back WRMT’s
worldwide exclusive license for the consumer self-monitoring market for 50% of the total NRE amounts actually paid by to GI less
any NRE repayments to WRMT according to the provisions in Section 3.1. Should GI choose not to exercise its option under this provision,
(i) this Agreement shall remain in effect through the end of the then-current term, at which time this Agreement will terminate;
(ii) all minimum volume purchase requirements shall expire, and (iii) the licenses granted to WRMT under Section 2.1 shall become
non-exclusive for the consumer self-monitoring market.

 

		7.4	On termination:

		a)	all rights granted to the Licensee under this License
shall cease;

		b)	the Licensee shall cease all activities authorised by this License; and

		c)	Upon early termination, GI will terminate all future work and return any and all unspent funds
allocated for the completion of the project that have previously been paid to GI by WRMT.

 

		8	FORCE MAJEURE

 

No Party shall be liable to
the other for any delay or non-performance of its obligations under this License arising from any cause beyond its reasonable control
including, without limitation, any of the following: act of God, governmental act, war, fire, flood, explosion or civil commotion.
For the avoidance of doubt, nothing in clause 8 shall excuse the Licensee from any payment obligations under this license.

 

		9	CONFIDENTIALITY AND PUBLICITY

 

		9.1	In connection with this Agreement, either Party may disclose
to the other Party its Information. Information of a disclosing Party is confidential or proprietary only if it is clearly marked
or otherwise identified by the disclosing Party as being confidential or proprietary, provided that if it is orally or visually
disclosed (including Information conveyed to an answering machine, voice mail box or similar medium), the disclosing Party must
designate it as confidential or proprietary within 30 days of disclosure. Notwithstanding the foregoing, a disclosing Party is
not obligated to mark, identify, or so designate, Information that the disclosing Party discloses to or is otherwise obtained
by the receiving Party’s employees, contractors, or representatives (i) who are located on the disclosing Party’s
premises; (ii) who access the disclosing Party’s systems; or (iii) who otherwise obtain Information in connection with this
Agreement, any such Information so disclosed is automatically deemed to be confidential and proprietary. Additionally, the failure
to mark or designate information as being confidential or proprietary will not waive the confidentiality where it is reasonably
obvious, under the circumstances surrounding disclosure, that the information is confidential or proprietary; any such information
so disclosed or obtained is automatically deemed to be confidential and proprietary. Information provided by either Party to the
other Party prior to the Effective Date of this Agreement in connection with the subject matter hereof, including any such Information
provided under a separate non-disclosure agreement (howsoever denominated) is also subject to the terms of this Agreement. Neither
Party has any obligation to the other Party with respect to Information that: i) at the time of disclosure was already known to
the receiving Party free of any obligation to keep it confidential (as evidenced by the receiving Party’s written records
prepared prior to such disclosure), ii) is or becomes publicly known through no wrongful act of the receiving Party (such obligations
ceasing at the time such Information becomes publicly known), iii) is lawfully received from a third party, free of any obligation
to keep it confidential, iv) is independently developed by the receiving Party or a third party, as evidenced by the receiving
Party’s written records, and wherein such development occurred without any direct or indirect use of or access to the Information
received from the disclosing Party, or v) the disclosing Party consents in writing to be free of restriction.

 

    	 	13	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		9.2	With respect to the Information of the disclosing Party,
the receiving Party must:

 

		a)	hold all such Information in confidence with the same
degree of care with which it protects its own Information, but with no less than reasonably prudent care;

 

		b)	restrict disclosure of such Information solely to its employees, contractors, and agents with a
need to know such Information, advise such persons of their confidentiality obligations under this Agreement with respect to the
Information, and ensure that such persons are bound by obligations of confidentiality reasonably comparable to those imposed in
this Agreement;

 

		c)	use such Information only as needed to perform its obligations under this Agreement;

 

		d)	except as necessary under Section 10.01(b)(iii), not copy, distribute, or otherwise use any such
Information or allow anyone else to copy, distribute, or otherwise use such Information; and ensure that any and all copies bear
the same notices or legends, if any, as the originals; and

 

		e)	upon the disclosing Party’s request, promptly return, or destroy all or any requested portion
of the Information, including tangible and electronic copies, notes, summaries, extracts, mail or other communications, and provide
written certification within fifteen business days to the disclosing Party that such Information has been returned or destroyed,
provided that with respect to archival or back-up copies of Information that reside on the receiving Party’s systems, the
receiving Party will be deemed to have complied with its obligations under this Section 9.2(b)(v) if it makes reasonable efforts
to expunge from such systems, or to permanently render irretrievable, such copies.

 

		9.3	The terms of this License are confidential and may not
be disclosed by either Party without the prior written consent of the other Party. Neither WRMT
nor GI will issue a press release or otherwise disclose that the two companies are working together without the consent of the
other party, provided that consent is not unreasonably withheld from the other party. Nothing in the foregoing, however,
shall prohibit a party from making such disclosures to the extent deemed necessary under applicable federal, state or provincial
securities laws or any rule or regulation of any securities exchange; in such event, however, the disclosing party shall use good
faith efforts to consult with the other party prior to such disclosure. Notwithstanding anything to the contrary in this Agreement,
GI understands and acknowledges that information related to the installation, operation, repair, or maintenance of the Deliverables
will not be considered confidential or proprietary, and WRMT may disclose any such information for purposes of installing, operating,
repairing, replacing, removing, and maintaining the Deliverables.

 

    	 	14	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		9.4	A receiving Party’s obligations with respect to
any particular Information of a disclosing Party remains in effect, for a period of five (5) years after the expiration or termination
of this Agreement; provided, however, that with respect to trade secrets of a disclosing Party, the confidentiality obligations
of the receiving Party shall remain in effect for so long as the disclosing Party continues to maintain the trade secrets as such.

 

		10	INDEMNIFICATION

 

		10.1	Definitions. For purposes of this Section 10:

 

“Indemnified
Parties” means WRMT and its Affiliates, as well as their agents, individually or collectively, as the case may be.

 

“Accused Elements”
means any products, hardware, software, systems, content, services, methods, documents, materials, data or information (or functionality
therein) provided by or on behalf of GI.

 

		10.2	Infringement Indemnity. GI agrees to indemnify,
hold harmless, and defend the Indemnified Parties against any costs, damages or expenses (each a “Loss”) resulting
from, arising out of or relating to any allegation, threat, demand, claim or lawsuit brought by any third party (“Covered
Claim”), regardless of whether such Covered Claim is meritorious, for infringement (including direct, contributory and
induced infringement) of any patent, copyright, trademark, service mark, or other intellectual property right in connection with
the Accused Elements, including, for example, any Covered Claim of i) infringement based on making or having made, repair, receipt,
use, importing, sale or disposal (and offers to do any of the foregoing) of Accused Elements, (ii) misappropriation of
any trade secret, proprietary or non-public information in connection with the Accused Elements (any and all such Loss referenced
in this Section is referred to as a “Covered Loss”).

 

GI shall have
no liability or obligation hereunder with respect to any Covered Claim if such Covered Claim is caused by (i) compliance with designs,
guidelines, plans or specifications of WRMT; (ii) use of any Licensed Product by WRMT or its customers in an application or environment
other than as specified in applicable Specifications; (iii) modification of any Licensed Product by any party other than GI or
the combination, operation or use of any Licensed Product with other product(s) not supplied by GI; or (iv) use of any Licensed
Product in the Integrated Product where the Licensed Product would not by itself be infringing. WRMT agrees to indemnify and hold
harmless GI from and against all liabilities, obligations, costs, expenses and judgments, including court costs, reasonable attorneys’
fees and expert fees, arising out of any of the circumstances stated in this Section.

 

GI retains
sole control over the defense and settlement of any Covered Claim. WRMT agrees to cooperate in every reasonable way with GI to
facilitate the defense and may, at its option and at its own expense, participate with GI in the defense with counsel of its own
choosing.

 

    	 	15	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		10.3	Continued Use of Accused Elements Upon Injunction. Without in any manner limiting the foregoing
indemnification, if, as a result of a Covered Claim, (1) Indemnified Parties’ rights under this Agreement are restricted
or diminished; or (2) an injunction, exclusion order, or other order from a court, arbitrator or other competent tribunal or governmental
authority preventing or restricting the Indemnified Parties’ use or enjoyment of the Accused Elements is issued, imminent,
or reasonably likely to be issued, then, in addition to its other obligations set forth in this Section 10.3 GI, in any case at
its sole expense and at no loss, cost or damage to the Indemnified Parties, agrees to use commercially reasonable efforts to obtain
for the Indemnified Parties the right to continue using or conducting other activities with respect to the Accused Elements; provided
that if GI is unable to obtain such right, GI must modified or replacement non-infringing Accused Elements that are equally suitable
and functionally equivalent while retaining the quality of the original Accused Elements and complying fully with all the representations
and warranties set forth in this Agreement; provided further that if GI is unable in this way to provide such modified or replacement
non-infringing Accused Elements, WRMT will have the right, without prejudice to any other rights or remedies that WRMT has in contract,
law or equity: (1) to terminate this Agreement; and (2) to require GI, as applicable, to remove, accept return of, or discontinue
the provision of the Accused Elements, to refund to WRMT that portion of the purchase price thereof or other monies paid therefor
amortized over a three (3) year period.

 

Notwithstanding any other provision
of this Agreement to the contrary, should an injunction be issued against any person (whether or not stayed or currently in effect),
affecting the Indemnified Parties’ ability to use or conduct other activities with respect to the Accused Elements, then
the Indemnified Parties may require GI to seek the right to continue to use, or conduct other activities with respect to, the Accused
Elements.

 

		10.4	Forbidden Settlements. GI is not authorized to settle any Covered Claim, in whole or in
part, in a manner that would require any Indemnified Party to modify or discontinue its products or services (or offerings thereof),
without WRMT’s prior written consent, which consent will not be unreasonably withheld.

 

		10.5	Exceptions. GI will not be liable or obligated to any of the Indemnified Parties for any
Loss resulting from an Covered Claim if and to the extent that such Covered Claim is clearly based on, and would not have arisen
but for:

 

		a)	use of the Accused Elements by the Indemnified Parties
in a manner that constitutes an uncured material breach of an explicit prohibition in this Agreement; or

 

		b)	a modification or alteration of the Accused Elements
by an Indemnified Party that is unauthorized by GI or the combination, operation or use of any Accused Element with other product(s)
not supplied by GI; or

 

		c)	GI’s contractually required conformance to the
Indemnified Party’s written specifications; or

 

		(d)	use of any Accused Element in the Integrated Product
where the Accused Element would not by itself be infringing

 

WRMT agrees
to indemnify and hold harmless GI from and against all liabilities, obligations, costs, expenses and judgments, including court
costs, reasonable attorneys fees and expert fees, arising out of any of the circumstances stated in this Section 10.5.

 

    	 	16	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		10.6	General Indemnity. Except where Licensor
is obligated to indemnify the Indemnified Parties as set forth in this Section 10, without limiting any obligation of WRMT to
indemnify Licensor under Section 10.5, Licensee (as the “Indemnifying Party”) will indemnify, hold harmless and defend
Licensor (as the “Indemnified Party”) from and against any and all losses, damages, expenses (including reasonable
attorneys’ and expert fees), claims, liabilities, suits or actions (“Claims”), arising from or in connection
with, or resulting from, Licensee’s development, testing, marketing, sale and distribution of the Integrated Products. In
addition to GI’s indemnification obligations set forth above, Licensor (as the “Indemnifying Party”) will indemnify,
hold harmless and defend Licensee, including its Affiliates and agents (as the “Indemnified Party”) from and against
any and all Claims, arising or resulting from or in connection with the intentional or grossly negligent acts or omissions of
Licensor pursuant to this Agreement, whether carried out by Licensor’s employees, agents or subcontractors. Licensee shall
not be obligated to indemnify Licensor with respect to any Claim is obligated to provide indemnification under this Section. The
foregoing indemnification obligations require that: (i) the Indemnified Party shall notify the Indemnifying Party in writing of
the Claim within a reasonable period of time after becoming aware of such claim or the Indemnifying Party’s potential culpability
and (ii) the Indemnifying Party has primary control of the defense and all related settlement negotiations. Failure of the foregoing
obligations shall affect the indemnification obligation only to the extent such failure materially and adversely impacts the ability
of the Indemnifying Party to successfully defend against the Claims. The Indemnifying Party agrees that any settlement of such
claim or cause of action shall release the Indemnified Party fully, absolutely, and finally from any liability related to such
cause of action. The Indemnifying Party shall minimize, to the extent possible, publicity adverse to the Indemnified Party associated
with any such settlement. The Indemnifying Party shall not agree to a settlement which names the Indemnified Party as culpable
absent the prior written consent of the Indemnified Party. In the event that the Indemnifying Party, in the reasonable judgment
of the Indemnified Party, lacks the financial resources to adequately and timely defend such claim or if the Indemnifying Party
has indicated in writing its unwillingness to so defend such claim, the Indemnified Party may defend and the Indemnifying Party
shall reimburse, all costs related to such defense.

 

		10.8	NOTWITHSTANDING ANY OTHER PROVISION IN THIS AGREEMENT
TO THE CONTRARY (AND WHETHER OR NOT SUCH A PROVISION CONTAINS LANGUAGE THAT REPRESENTS ITSELF AS TAKING PRECEDENCE OVER OTHER
PROVISIONS CONTRARY TO IT), WHETHER EXPRESS OR IMPLIED, NONE OF THE LIMITATIONS OF LIABILITY (INCLUDING ANY LIMITATIONS REGARDING
TYPES OF OR AMOUNTS OF DAMAGES OR LIABILITIES) CONTAINED ANYWHERE IN THIS AGREEMENT WILL APPLY TO A PARTY’S OBLIGATIONS
UNDER THIS SECTION 10.

 

		11	LIMITATION OF LIABILITY

 

Without limiting Indemnification
and Confidentiality obligations set forth in this Agreement, in no event shall (i) either Party be liable to the other for any
punitive, special, indirect, consequential or incidental damages arising out of this Agreement, however caused, based on any theory
of liability, and (ii) GI’s aggregate liability for all direct damages arising out of the subject matter of this Agreement,
whether in contract, tort or otherwise, exceed one hundred fifty percent (150%) the payment amounts actually received by GI from
WRMT hereunder.

 

    	 	17	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		12	WAIVER

 

No forbearance or delay by either Party
in enforcing its rights shall prejudice or restrict the rights of that Party, and no waiver of any such rights or of any breach
of any contractual terms shall be deemed to be a waiver of any other right or of any later breach.

 

		13	SEVERABILITY

 

If any provision of this License is judged
to be illegal or unenforceable, the continuation in full force and effect of the remainder of the provisions shall not be prejudiced.
The Parties will negotiate in good faith to replace the unenforceable provision with an enforceable provision with effect nearest
to that of the provision being replaced.

 

		14	AMENDMENTS

 

Any amendment, waiver or variation of this
License shall not be binding on the Parties unless set out in writing, expressed to amend this License and signed by or on behalf
of each of the Parties.

 

		15	ASSIGNMENT

 

Except as otherwise provided in this Section,
neither Party may assign this Exclusive License Agreement or any of its rights or obligations under this Agreement without the
prior written approval of the other Party. Any attempted assignment, delegation or transfer without the necessary approval will
be null and void. Notwithstanding the foregoing, either Party may assign or transfer this Agreement without the prior written approval
of, but with no less than thirty (30) days prior written notice to, the other to a third party controlled by or under common control
with the transferor; or (ii) in connection with a sale of all or substantially all of the Party’s assets or all or substantially
all of the assets to which this Agreement relates, unless the sale occurs during the work to be performed as set forth in Section
3.1 above and the time period specified in Appendix E, in which case prior written approval is required. Any transferee must agree
to be bound by the same rights and obligations to which the transferor is bound under this Agreement.

 

		16	THIRD PARTY RIGHTS

 

Notwithstanding any other provisions of
this Agreement, nothing in this Agreement confers or purports to confer any right to enforce any of its terms on any person who
is not a party to it. This Exclusive License Agreement is binding upon, inures to the benefit of, and is enforceable by the Parties
and their respective successors and permitted assigns. Licensor agrees that Licensee Affiliates are intended third party beneficiaries
of this Exclusive License Agreement and are entitled to rely upon all rights representations, warranties, and covenants made by
Licensor herein to the same extent as if each affiliate were Licensee hereunder.

 

    	 	18	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		17	NOTICES

 

Any notice required to be given pursuant
to this Exclusive License Agreement shall be in writing, and shall be sent to the other Party marked for the attention of the person
at the address set out for such Party in this Exclusive License Agreement. Notices may be sent by first-class mail or fax, with
a confirmation email copy sent to the authorised email address at the time the notice is sent. Correctly addressed notices sent
by first-class mail shall be deemed to have been delivered 72 hours after posting and correctly directed faxes shall be deemed
to have been received instantaneously on transmission subject to receipt of an acknowledgement of successful transmission.

 

Notices shall be sent to:

 

Giner Inc.

89 Rumford Ave.Newton, MA 02466

Fax: 781-893-6470

Email: cmittelsteadt@ginerinc.com

 

World Media & Technology
Corp.

Address: 600 Brickell Ave.,
Suite 1775

Miami, Florida 33131

Email: f.galdi@worldmediatech.com

 

		18	ENTIRE AGREEMENT

 

This Exclusive License Agreement contains
the whole agreement between the Parties relating to the subject matter hereof and supersedes all prior agreements, arrangements
and understandings between the Parties relating to that subject matter, including without limitation and previously executed confidentiality
agreement.

 

		19	GOVERNING LAW AND JURISDICTION

 

		a)	This Agreement, the rights and obligations of the parties
hereto, and any claims or disputes relating thereto, shall be governed by and construed in accordance with the laws of the State
of Delaware.

 

		b)	If a dispute arises out of or relates to this Agreement or its breach (the “Matter”),
the parties agree to resolve the Matter as follows:

 

		i)	a party (the “Initiating Party”) shall submit
written notice of the Matter to the other parties and request negotiation;

 

		ii)	the parties shall attempt in good faith to resolve any
Matter arising out of or relating to this Agreement promptly by negotiation between representatives which the parties may appoint,
and

 

		iii)	if the Matter has not been resolved within 30 days of
a party’s request for negotiation, either party may request that the Matter be submitted to a sole mediator selected by
the parties for mandatory mediation of not more than five days’ duration.

 

    	 	19	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		c)	If the Matter has not been resolved by such mediation, either party may submit the Matter for binding
arbitration, without limiting either Party’s right to seek appropriate injunctive relief, if the Parties are unable to promptly
resolve a dispute informally or by mediation, the Party alleging a material breach (the “Moving Party”) may
initiate arbitration by providing the other Party written notice of its intent to arbitrate. If the Parties are unable to agree
upon an arbitrator within three business days of the Moving Party’s written notice to arbitrate, the Moving Party may request
the American Arbitration Association (“AAA”) to appoint an arbitrator. The AAA will then select an arbitrator
who can promptly proceed with and strive to conclude the arbitration as specified herein. If a dispute is submitted to an arbitrator,
it must be finally resolved through binding arbitration in Santa Clara, California, according to the Commercial Arbitration Rules
of the AAA, except as modified in this Agreement. The award rendered by the arbitrator is final and binding on the Parties and
is deemed enforceable in any court having jurisdiction over the matter. The arbitration will be heard by a single arbitrator who
must, by training, education, or experience, have knowledge of the general subject matter of this Agreement. The arbitrator will
have only the power to award damages, injunctive relief and other remedies to the extent the same would be available in a court
of law having jurisdiction of the matter, except that the arbitrator will not have the power to vary the provisions of this Agreement.
The arbitrator must promptly commence the arbitration proceeding with the intent to conclude the proceedings and issue a written
decision stating in reasonable detail the basis for the award, which must be supported by law and substantial evidence, as promptly
as the circumstances demand and permit, but generally no later than ten weeks after the arbitrator’s appointment. Each Party
acknowledges that it is giving up judicial rights to a jury trial, discovery and most grounds for appeal under the foregoing provision.

 

		d)	The parties shall not be entitled to rely on or introduce as evidence before any arbitral proceedings
whether or not such proceedings relate to the Matter that is the subject of the negotiations:

 

		i)	views expressed or suggestions made by another party in respect of a possible settlement of the Matter;

 

		ii)	admissions or proposals made by another party in the course of negotiations; or

 

		iii)	the fact that the other party had indicated his willingness to accept a proposal for settlement
made by another party.

 

		e)	The mediation and arbitration shall be held in Delaware. The parties, their representatives, the
mediator and the arbitrator shall hold the existence, content and results of any negotiation, mediation or arbitration in confidence
unless disclosure is required by law or regulation, and in such case the parties shall take reasonable precautions to only disclose
what is required by the law or governmental regulation.

 

		f)	Any award of the Arbitration shall be final and binding on the parties and shall be enforceable
in any court having jurisdiction over the party from whom enforcement is requested. The prevailing Party is entitled to recover
from the non-prevailing Party the reasonable attorneys’ fees, expenses and costs incurred by the prevailing Party in any
arbitration.

 

*** Signature Page to Follow ***

 

    	 	20	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

	AGREED AND UNDERSTOOD:	 
	 	 
	LICENSOR	 
	GINER, INC.	 
	 	 	 
	By:	 	 
	 	 	 
	Name:  	 	 
	 	 	 
	Title:  	 	 
	 	 	 
	Date:  	 	 
	 	 	 
	LICENSEE	 
	WORLD MEDIA & TECHNOLOGY CORP.	 
	 	 	 
	DATE:	 	 
	 	 	 
	By:	/s/ Fabio Galdi	 
	Fabio Galdi	 
	Chief Executive Officer	 

 

    	 	21	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

Appendix A

Gantt Chart

 

 

    	 	22	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

Appendix B

Description of the Licensed Products
and related Intellectual Property Rights 

 

The TAS unit.

 

The Advanced App.

 

The existing transdermal alcohol sensor (TAS)
technology, any updates or enhancements thereto and any newly developed TAS technology, and their related Intellectual Property
Rights

 

Consisting specifically of:

 

		1.	US Nonprovisional Patent No. 5,944,661 for the original
transdermal alcohol sensor technology.

 

		2.	US Provisional Patent No. 62/447,214 for a data analysis
algorithm that correlates transdermal alcohol sensor response to the user’s subjective feelings of intoxication.

 

		3.	GI expects to file a nonprovisional patent for the “waterless”
transdermal alcohol sensor technology by mid-2017, which would be subject to this Agreement

 

		4.	All future patents related to the GI’s transdermal
alcohol sensor technology occurring during the Term of this Agreement.

 

		5.	GI’s trade secrets related to transdermal alcohol
sensor technology, including, but not limited to, TAS units currently sold to collaborators and commercial partners, the WrisTAS
7 sensing component and all previous sensing component versions, the WrisTAS 7 device, a miniaturized “waterless”
TAS sensing component, potentiostatic circuitry, electronic circuit layout and design for the TAS sensor, sensor hardware, sensor
software, data analysis algorithms, calibration methods, calibration curves and values, and manufacturing know-thereof.

 

		6.	GI’s trademark for “WrisTAS”.

 

    	 	23	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

Appendix C1

Funding Payment Schedule

 

$750K upon project
startup

$300K 3 months
after project startup

$275K 6 months
after project startup

$275K 9 months
after project startup

 

Project startup will be the Effective Date
of this Agreement.

 

The first element of the NRE cost will provide
for the automation/scale-up of the manufacturing process to support a capacity of at least 1million units per year.

 

The second element of the NRE cost will provide
for design support to WRMT in integrating the sensor into the Helo 2.0 device, development of an advanced data analysis app, longevity
and human testing of the prototype TAS device, and support for the integration of data analysis algorithms and calibration implemented
into the Helo 2.0 device.

 

GI and WRMT recognize that specialized packaging
may be needed for integrating the delivered TAS units into WRMT’s manufacturing system, and this specialized packaging may
require additional NRE funding.

 

    	 	24	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

Appendix C2

 

Per Unit Pricing*

 

	0 to 250K TAS units :	$9/unit
	250K+ to 500K TAS units :	$8/unit
	500K+ to 750K TAS units :	$7/unit
	750K+ to 1M TAS units :  	$6/unit
	1M+ to 2.5M TAS units:	$5/unit
	2.5M+ to 5M TAS units:	TBD
	5.0M+ TAS units:	TBD
	 	 
	*K = thousand; M= Million	 

 

If subsequent sales in a given year reach
a new volume-based price range, GI will rebate the difference between the new volume-based price range and the volume-based price
range of the previous sales. For instance, if WRMT initially purchases 250K at $9 per TAS unit and subsequently purchases 250K
more at $8 per TAS unit, GI will provide a rebate to WRMT for the difference of $1 per TAS unit for the previous 250K TAS units
purchased.

 

Appendix C3

 

Minimum Volumes*

 

Year 1: 200K
TAS units

Year 2: 500K
TAS units

Year 3: 1M
TAS Units

Year 4: 2M
TAS Units

Year 5: 3M
TAS Units*

 

*1 year = 1 calendar year, starting on
the date specified in Section 3.4.

* K= thousand; M = million

*WRMT and GI will negotiate in good faith
for the purpose of establishing a joint venture upon 3 million in TAS unit sales.

 

    	 	25	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

APPENDIX D

 

GI Technical Support and Maintenance

 

During the NRE Phase, Giner shall supply
the following technical support and maintenance:

 

		1.	All drawings related to the miniaturized “waterless”
TAS unit and associated electronics.

 

		2.	Technical support will be provided to WRMT’s design
partners for integrating the TAS unit and electronics into the Helo device.

 

		3.	Technical support for data collection algorithms, including
a protocol for calibrating the TAS unit.

 

		4.	Feedback on Giner’s testing of the Helo 2.0 alpha
device with the integrated TAS unit, including any modifications the TAS unit or associated electronics.

 

		5.	Technical support for integrating TAS sensor output from
the CPU into Helo’s hardware SDK.

 

		6.	Technical support and drawings for the final TAS design
to be integrated in the final commercial version of the Helo 2.0 device.

 

    	 	26	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

APPENDIX E

 

Integration Statement of Work

 

OVERALL TIMELINE:

 

Three (3) months to integrate the
technology into Helo 2.0

Three (3) months rigorous testing

Three (3) months to finalize Beta
product and launch mass production 100K – 1M units/year.

 

PROJECT DESCRIPTION:

 

A miniaturized “waterless” TAS
sensor that is able to passively and non-invasively detect alcohol diffusing through the skinIt is expected that these sizes provided
in the Specifications should be adequate for Helo 2.0 and it should be noted that further miniaturization could be costly and time
consuming as a technology change and further testing would be required.

 

GI will supply the TAS units for the final
commercial Helo 2.0 product and successor products. WRMT will supply the TAS housings and stack-up, approved by GI during the NRE
design phase, for the final commercial Helo 2.0 product and successor products.

 

SPECIFICATIONS:

 

	Packaged Sensor Dimensions: 	0.580” in diameter and 0.220” in height, or less.
	Sensing Component Dimensions: 	0.380” in diameter and 0.020” in height, or less.
	Membrane Tolerance:	+/-5% the dimension of the final design.
	Electrode Tolerance:	+/-5% the dimensions of the final design.
	Electrode Orientation:	<2o the angle of the final design.
	Alcohol Sensor Response:	>2.0microAmps for a 10mg/dL standard calibration solution.
	Resistance Testing:	Each TAS unit will be checked for shorts or high resistance before shipment.

 

    	 	27	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

APPENDIX F

 

Advanced App

 

Project Description:

A mobile software application with transdermal
alcohol response data in engineering units and with advanced features, such as a hangover alert

 

Specifications: 

1. SDK Integration.  GI will
provide access to all of the alcohol raw signal that is used in the Advanced App, to WRMT’s chosen Helo App Store developer
via API so it can provide raw signal to other 3rd party API developers in WRMT’s SDK library.  

2. Login/Registration Page. GI will provide
registration page with username and login.

3. Syncing Device. After initial registration,
GI will have the user sync their Smartphone to the Helo to obtain the alcohol data (if the syncing was not done already through
the main Helo app).

4. Data Transmission. The raw output
from the alcohol sensor ADC on Toshiba CPU will be transmitted via BLE to the Smartphone, and used to calculate the %BAC values.

5. Sensor Calibration. GI will provide
the calibration factors for each sensor used to convert the raw signal coming from the ADC. The calibration will be dynamic in
that it will change over time, and Giner will supply the software algorithm to adjust the calibration

6. Advanced App Features. GI will provide
one or more advanced app features, such as (1) a “Hangover Alert” that correlates a user’s subjective feelings
of intoxication to their response curve and uses that correlation to offer an drinking pace alert during future events, and (2)
an algorithm giving an estimate of time until sobriety while a user is drinking.

7. Graphical Data. GI will provide
a graph of the user’s alcohol response over the last 8-24 hours.

8. Historical Data. GI will provide
a summary of drinking behaviour, such as number of drinks and how often the user drinks, over a specified time period (e.g. over
the previous year).

9 “Big Data” Transmission.
For the user’s that consent to the use of their data, the app will send their user drinking data to WRMT’s “Big
Data” storage system.

10. Payment System. For any user app
payments, GI will integrate will PayNovi’s payment system.

11. OS Updates. GI will provide updates
to the app as iOS and Android update their OS’s.

12. Device Updates. GI will update the app
as new Helo versions become available from WRMT.

 

Timeline: 

GI will provide pre-launch testing of the
app estimated at ~6 months from startup. After the pre-launch testing, GI will make any necessary modifications and adjustments
to the app, and the app will be finalized at least 1 week before the end of the 9-month NRE time period.

 

Consideration Terms:

		a)	GI will receive 30% of the Net Revenue generated
by sales of the Advanced App developed by GI under the terms set forth in the Helo App Store Standard App Agreement
which will be placed on the following website:  http://www.heloappstore.com/.”

 

		a.	Net Revenue means the total amount charged to, and received
from, customers for an Advanced App sale, less all platform application download fees (using iTunes charges as the benchmark),
taxes, customer charge-backs or refunds, and transactions processing fees (processing fees are capped at seven percent (7%) of
the gross amount).

 

    	 	28	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties
	 

     

    

 

		b)	In lieu of revenue-sharing payments generated by third-party API developers from the use of GI’s
transdermal alcohol sensor, WRMT will provide an additional sensor enablement fee of $0.25 per sensor for the use of GI’s
transdermal alcohol sensor in third-party apps.

 

		c)	GI will apply the revenue received from purchases of the Advanced App and the sensor enablement fee
against the NRE cost up to a total of 50% of the total NRE cost.

 

		d)	If GI enters one of the excluded markets that uses the transdermal alcohol sensor that is the same
or materially similar to the design developed under this NRE and the excluded market generates sales up to 100K TAS units per year,
GI will reimburse WRMT for additional 25% of the total NRE cost to be also paid back from the purchases of the Advanced App and
the sensor enablement fee.

 

Schedule 5.4

 

Complete List of Contracts with GI

 

GI has an existing relationship with BI, Inc.
for the purchase of WrisTAS 7 sensing components for use in the law enforcement market. GI has no long-term contract with BI, as
BI generally places new orders for product about every two (2) months.

 

    	 	29	 
	 	 	 
	 	Proprietary and Confidential
This Agreement and information contained therein is not for use or disclosure outside of WRMT, its Affiliates, and third party representatives, and GI except under written agreement by the contracting parties

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]